Clinical Trials | A study for patients with Small Cell Lung Cancer receiving Tarlatamab. The study aim is to decrease the serious immune-reaction side-effect of Tarlatamab, called Cytokine Release Syndrome, by using two days of the medicine, dexamethasone, by mouth.

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over who have Small Cell Lung Cancer (SCLC) or another diagnosis that is approved for use of Tarlatamab. The purpose of this study is to find out whether taking oral dexamethasone for two days before the first and second doses of tarlatamab in the first cycle of treatment can reduce the chance of developing Cytokine Release Syndrome (CRS) and/or make CRS less severe. CRS is a potentially serious immune reaction that can cause symptoms such as fever, low blood pressure, or difficulty breathing. In this study, you will receive dexamethasone by mouth for two days before the first and second doses of tarlatamab, in addition to the standard dexamethasone given before the infusions. All participants in this study will receive the study medication; there is no randomization or placebo group. Your time in the study will depend on how you respond to the tarlatamab. You will remain in the study at least 4 months unless you do not tolerate dexamethasone or tarlatamab and either of the drugs are stopped. Taking part in this study is voluntary. Choosing not to participate will not affect your medical care or your relationship with your healthcare providers. For questions, contact: [email protected]